Drug ID: 2d00000008
Drug Name: Basiliximab
Generic Names: Simulect
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category B
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.
Recommended Dose: Adult: The recommended dose is 20 mg within 2 hours before transplant. Repeat once 4 days later.
Recommended In: This medication is a monoclonal antibody, prescribed for prevention of rejection in renal transplant patients. It prevents transplanted organ by decreasing the activity of the body's immune system.
Directions For Use: It comes as a solution for injection to be administered by a healthcare provider into the vein.
Storage: Store it in refrigerator (2° to 8°C), and in an airtight container.
Dosage Forms: Intravenous Injection
Side Effects: Most Common - Pimples, constipation, diarrhea, headache, indigestion, nausea, runny nose, sleeplessness, stomach pain, tremor and vomiting.
Gastrointestinal - Abdominal pain.
Body as a Whole - Swelling in the extremities, fever and viral infection.
Metabolic - Increase in blood sugar/fat/potassium level.
Genitourinary - Urinary tract infection.
Respiratory - Difficulty in breathing and upper respiratory tract infection.
Skin - Surgical wound complications.
Heart - High blood pressure.
Blood - Anemia, bleeding, bruising and decrease in platelets.
In Case of Overdose: No significant overdose reported yet.
Avoid If: Caution should be exercised in patients with history of allergy, elderly, during pregnancy and breastfeeding.
It may affect blood sugar, monitor sugar level regularly while taking this medication.
Avoid contact with people who have infection.
Drug Interaction: Total body clearance of basiliximab was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.